Certified by Founder Lodge
Catalio Capital Management
United States - New York, NY
INVESTOR
1 Disclosed Funding Rounds $89,000,000
23 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Managem
Company | Date | Round | Raised |
---|---|---|---|
Avalyn Pharma Inc. | September, 28 ,2023 | Series C | $175,000,000 |
xilis | July, 13 ,2022 | Series A | $89,000,000 |
Iambic Therapeutics | October, 06 ,2023 | Series B | $100,000,000 |
Ensoma | February, 06 ,2023 | Series B | $85,000,000 |
Odyssey Therapeutics | December, 06 ,2023 | Series C | $101,000,000 |
Volastra Therapeutics | March, 08 ,2023 | Series A | $60,000,000 |
Lassen Therapeutics | December, 21 ,2023 | Series B | $85,000,000 |
Septerna | July, 18 ,2023 | Series B | $150,000,000 |
NextPoint Therapeutics, Inc. | February, 15 ,2024 | Series B | $42,500,000 |
Georgiamune Inc. | August, 10 ,2023 | Series A | $75,000,000 |
FogPharma | March, 05 ,2024 | Series E | $145,000,000 |
Star Therapeutics | September, 05 ,2023 | Series C | $90,000,000 |
PinkDx, Inc. | April, 26 ,2024 | Series A | $40,000,000 |
NOETIK | September, 08 ,2023 | Seed | $14,000,000 |
INSIGHTEC | June, 20 ,2024 | Unknown | $150,000,000 |
Avalyn Pharma Inc. | September, 28 ,2023 | Series C | $175,000,000 |
Iambic Therapeutics | October, 06 ,2023 | Series B | $100,000,000 |
Odyssey Therapeutics | December, 06 ,2023 | Series C | $101,000,000 |
Lassen Therapeutics | December, 21 ,2023 | Series B | $85,000,000 |
NextPoint Therapeutics, Inc. | February, 15 ,2024 | Series B | $42,500,000 |
FogPharma | March, 05 ,2024 | Series E | $145,000,000 |
PinkDx, Inc. | April, 26 ,2024 | Series A | $40,000,000 |
INSIGHTEC | June, 20 ,2024 | Unknown | $150,000,000 |